Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014)
Neurogene (NGNE) reported Non-Current Deferred Tax Liability of $1.8 million for Q4 2014, little changed on a YoY basis from $1.8 million in Q4 2013, and little changed quarter-over-quarter from $1.8 million in Q1 2014.
Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014) Analysis & Trends
Neurogene has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $1.8 million in Q4 2014.
- For the quarter ending Q4 2014, Non-Current Deferred Tax Liability changed 0.02% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2014 stood at $1.8 million (changed 0.02% YoY), and the FY2014 full-year result was $1.8 million, changed 0.02% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2014 stood at $1.8 million, roughly flat from $1.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $1.8 million in Q4 2013, with the low at $1.8 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 1.80 Mn |
| Dec 31, 2014 | 1.80 Mn |
| Mar 31, 2014 | 1.80 Mn |
| Mar 31, 2014 | 1.80 Mn |
| Dec 31, 2013 | 1.80 Mn |
| Dec 31, 2013 | 1.80 Mn |